Predicting osteoradionecrosis risk in patients with locoregionally advanced nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: the value of the

被引:0
|
作者
Durankus, Nilufer Kilic [1 ]
Somay, Efsun [2 ]
Bascil, Sibel [3 ]
Senyurek, Sukran [1 ]
Ozturk, Duriye [4 ]
Selek, Ugur [1 ]
Topkan, Erkan [5 ]
机构
[1] Koc Univ, Sch Med, Dept Radiat Oncol, Istanbul, Turkiye
[2] Baskent Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Ankara, Turkiye
[3] Baskent Univ, Fac Dent, Dept Periodontol, Ankara, Turkiye
[4] Afyonkarahisar Hlth Sci Univ, Fac Med, Dept Radiat Oncol, Afyonkarahisar, Turkiye
[5] Baskent Univ, Fac Med, Dept Radiat Oncol, Adana, Turkiye
关键词
C-reactive protein-to-albumin ratio; weight loss; CARWLindex; osteoradionecrosis; nasopharyngeal carcinoma; NECK-CANCER PATIENTS; LYMPHOCYTE RATIO; SOLID TUMORS; HEAD; CHEMOTHERAPY; MANAGEMENT;
D O I
10.17305/bb.2024.11155
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Osteoradionecrosis is a severe complication that can arise in patients with nasopharyngeal carcinoma due to the aggressive nature of chemoradiotherapy treatment. The purpose of our study was to assess the utility of the recently introduced CARWL index, which integrates the C-reactive protein-to-albumin ratio (CAR) and significant weight loss (SWL), in predicting the risk of osteoradionecrosis (ORN) in patients with locoregionally advanced nasopharyngeal cancer (LA-NPC) undergoing concurrent chemoradiotherapy (CCRT). We conducted a retrospective cohort analysis on 304 patients with LA-NPC treated with CCRT. Patients were categorized into CARWL index groups based on CAR (cut-off: 3.0) and SWL (weight loss > 5% over the past six months): CARWL-0 (CAR < 3.0, SWL <= 5%), CARWL-1 (CAR < 3.0 with SWL > 5% or CAR >= 3.0 with SWL <= 5%), and CARWL-2 (CAR >= 3.0 and SWL > 5%). The primary endpoint was the incidence of ORN in each CARWL index group. At a median follow-up of 67.2 months, 28 patients (9.2%) developed ORN. The incidence of ORN was 2.1%, 9.4%, and 16.3% in the CARWL-0, CARWL-1, and CARWL-2 groups, respectively (P < 0.001). Multivariate analysis identified smoking status (HR: 2.58, P = 0.034), N-stage (HR: 1.96, P = 0.008), T-stage (HR: 1.84, P = 0.017), pre-CCRT tooth extraction status (HR: 5.81, P < 0.001), post-CCRT tooth extraction status (HR: 6.82, P < 0.001), mandibular V55.8 Gy (HR: 6.12, P < 0.001), and CARWL score (HR: 5.67, P = 0.002) as significant predictors of ORN. The CARWL index is a reliable predictive tool for evaluating the risk of ORN in LA-NPC patients undergoing CCRT. If further validated, its use in clinical settings could aid in the early identification of high-risk patients and enable the implementation of personalized preventive strategies.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma
    Chen, Lin
    Li, Kunpeng
    Li, Qingjie
    Ji, Pengjie
    Huang, Chenglong
    Tang, Linglong
    [J]. RADIOTHERAPY AND ONCOLOGY, 2024, 200
  • [2] Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma
    Feng, Hui-Xia
    Guo, Su-Ping
    Li, Gui-Rong
    Zhong, Wen-Huan
    Chen, Liu
    Huang, Li-Ru
    Qin, Hui-Ying
    [J]. MEDICAL ONCOLOGY, 2014, 31 (09) : 1 - 6
  • [3] Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma
    Hui-Xia Feng
    Su-Ping Guo
    Gui-Rong Li
    Wen-Huan Zhong
    Liu Chen
    Li-Ru Huang
    Hui-Ying Qin
    [J]. Medical Oncology, 2014, 31
  • [4] Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Locoregionally Advanced Nasopharyngeal Carcinoma
    Yu, Hong-Sheng
    Wang, Xin
    Song, Ai-Qin
    Liu, Ning
    Zhang, Wei
    Yu, Li
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (08) : 3961 - 3965
  • [5] Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma
    Poon, D
    Yap, SP
    Wong, ZW
    Cheung, YB
    Leong, SS
    Wee, J
    Tan, T
    Fong, KW
    Chua, ET
    Tan, EH
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05): : 1312 - 1318
  • [6] Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma
    Yao, Ji-Jin
    Zhang, Lu-Lu
    Gao, Tian-Sheng
    Peng, Ying-Lin
    Lawrence, Wayne R.
    Zhang, Wang-Jian
    Zhang, Fan
    Zhou, Guan-Qun
    Wang, Si-Yang
    Sun, Ying
    [J]. CANCER BIOLOGY & THERAPY, 2018, 19 (12) : 1102 - 1107
  • [7] Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: is Intergroup Study 0099 feasible in Japanese patients?
    Isobe, K
    Kawakami, H
    Uno, T
    Yasuda, S
    Aruga, T
    Ueno, N
    Kawata, T
    Ito, H
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (10) : 497 - 500
  • [8] Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma
    Wang, Yueshu
    Ding, Wei
    Chen, Chuang
    Niu, Zhihao
    Pan, Ming
    Zhang, Hong
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (06) : C191 - C195
  • [9] Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma
    Zhang, Wendong
    Dou, Huiqin
    Lam, Chileong
    Liu, Jixi
    Zhou, Jianfeng
    Liu, Yunsheng
    Wang, Xiuwen
    [J]. TUMOR BIOLOGY, 2013, 34 (03) : 1729 - 1736
  • [10] The effect of cisplatin dose administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
    Loong, H. H. F.
    Ma, B.
    Mo, F.
    Leung, S. F.
    Hui, E. P.
    Kam, M. K.
    Chan, S. L.
    Chan, A. T. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)